Kooij Louise Frederika 4

What Happened

• Louise Frederika Kooij, Chief Accounting Officer of NewAmsterdam Pharma (NAMS), exercised stock options and immediately sold the shares in open-market transactions. She exercised 39,816 options on Jan 27, 2026 (paying $10.90/share) and sold those 39,816 shares the same day at a weighted-average $32.62/share for $1,298,798. On Jan 28, 2026 she exercised another 32,612 options (paying $10.90/share) and sold those 32,612 shares that day at a weighted-average $31.80/share for $1,037,062.
• Total exercised shares: 72,428 (cash paid $789,465). Total sale proceeds: $2,335,860. Net proceeds after exercising the options (gross, before fees/taxes): about $1,546,395.

Key Details

• Transaction dates and prices:
  • 2026-01-27: Exercised 39,816 options @ $10.90; sold 39,816 shares @ weighted avg $32.62 (sales ranged $32.29–$32.97). (Footnote F1)
  • 2026-01-28: Exercised 32,612 options @ $10.90; sold 32,612 shares @ weighted avg $31.80 (sales ranged $31.58–$32.53). (Footnote F2)
• The filing shows corresponding derivative dispositions at $0.00, reflecting the options being exercised and the derivative ceasing.
• Shares owned after the transactions are not disclosed in the excerpt provided.
• Footnote F3: The options were granted Jan 1, 2023 with a standard four‑year vesting schedule (25% at one year, then monthly vesting over three years).
• Filing date: Jan 29, 2026 (covers transactions on Jan 27–28). That filing date is within the typical two-business-day Form 4 reporting window and appears timely.

Context

• This was an option exercise followed by immediate open‑market sales (a cashless or “exercise-and-sell” pattern). Such transactions convert vested option value into cash and are common for employees exercising vested awards to cover exercise cost and taxes.
• The filing is factual and does not indicate insider motivation; sales after option exercise are commonly routine liquidity events rather than directional bets on the stock.